Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.870517/full |
| _version_ | 1819061659638956032 |
|---|---|
| author | Mingchao Shi Fengna Chu Feiqi Zhu Jie Zhu Jie Zhu |
| author_facet | Mingchao Shi Fengna Chu Feiqi Zhu Jie Zhu Jie Zhu |
| author_sort | Mingchao Shi |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD. |
| first_indexed | 2024-12-21T14:46:24Z |
| format | Article |
| id | doaj.art-c71ffc247ae445d1870e676d143f9263 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-12-21T14:46:24Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-c71ffc247ae445d1870e676d143f92632022-12-21T19:00:00ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-04-011410.3389/fnagi.2022.870517870517Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and LecanemabMingchao Shi0Fengna Chu1Feiqi Zhu2Jie Zhu3Jie Zhu4Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Neurology, Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaCognitive Impairment Ward of Neurology Department, The Third Affiliated Hospital of Shenzhen University Medical College, Shenzhen, ChinaDepartment of Neurology, Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaDivision of Neurogeriatrcs, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, SwedenAlzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD.https://www.frontiersin.org/articles/10.3389/fnagi.2022.870517/fullAlzheimer’s diseaseamyloid-βmonoclonal antibodieslecanemabaducanumabtreatment |
| spellingShingle | Mingchao Shi Fengna Chu Feiqi Zhu Jie Zhu Jie Zhu Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab Frontiers in Aging Neuroscience Alzheimer’s disease amyloid-β monoclonal antibodies lecanemab aducanumab treatment |
| title | Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab |
| title_full | Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab |
| title_fullStr | Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab |
| title_full_unstemmed | Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab |
| title_short | Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab |
| title_sort | impact of anti amyloid β monoclonal antibodies on the pathology and clinical profile of alzheimer s disease a focus on aducanumab and lecanemab |
| topic | Alzheimer’s disease amyloid-β monoclonal antibodies lecanemab aducanumab treatment |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.870517/full |
| work_keys_str_mv | AT mingchaoshi impactofantiamyloidbmonoclonalantibodiesonthepathologyandclinicalprofileofalzheimersdiseaseafocusonaducanumabandlecanemab AT fengnachu impactofantiamyloidbmonoclonalantibodiesonthepathologyandclinicalprofileofalzheimersdiseaseafocusonaducanumabandlecanemab AT feiqizhu impactofantiamyloidbmonoclonalantibodiesonthepathologyandclinicalprofileofalzheimersdiseaseafocusonaducanumabandlecanemab AT jiezhu impactofantiamyloidbmonoclonalantibodiesonthepathologyandclinicalprofileofalzheimersdiseaseafocusonaducanumabandlecanemab AT jiezhu impactofantiamyloidbmonoclonalantibodiesonthepathologyandclinicalprofileofalzheimersdiseaseafocusonaducanumabandlecanemab |